Catalent Pharma Solutions will acquire Aptuit‘s Clinical Trial Supplies business for $410 million in a cash and debt free basis. The acquisition is intended to substantially expand Catalent’s Development & Clinical Services business, transforming it into the second largest global provider of clinical supply solutions. After the transaction, Aptuit will focus on its integrated discovery to mid-phase development business. “This transaction builds important expertise, scale and capabilit...